Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846024 | 0.96 | GLP1R (0.37) | GLP1RSIRT2LPAR3HPGDMEN1 | |
| SCHEMBL13567279 | 0.86 | HPGD (0.43) | GLP1RSIRT2HPGDMEN1ALDH1A1 | |
| SCHEMBL21845955 | 0.83 | GLP1R (0.33) | GLP1RHPGDHTTSMN1; SMN2 | |
| SCHEMBL13743054 | 0.80 | GLP1R (0.43) | GLP1RSIRT2LPAR3HPGDMEN1 | |
| SCHEMBL30391652 | 0.79 | MMP13 (0.39) | GLP1R | |
| SCHEMBL30391595 | 0.79 | SELP (0.35) | GLP1R | |
| SCHEMBL13256493 | 0.79 | SMN1; SMN2 (0.40) | HPGDMEN1ALDH1A1KMT2AHTT | |
| SCHEMBL16328781 | 0.78 | LPAR3 (0.47) | GLP1RSIRT2LPAR3HPGDMEN1 | |
| SCHEMBL30391948 | 0.78 | MMP13 (0.38) | GLP1R | |
| SCHEMBL30392491 | 0.78 | MMP13 (0.38) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, IAPP, INSR | GLP1R 38/4885SIRT2 2508/4885LPAR3 4187/4885 |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | GPR119, IAPP, INSR | GLP1R 38/4885SIRT2 2508/4885LPAR3 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.